Peer-influenced content. Sources you trust. No registration required. This is HCN.

MedPage TodayClinical Challenge: Hematologic Malignancy and COVID-19

The inaugural report of the ASH Research Collaborative (RC) COVID-19 Registry for Hematology, published in Blood Advances, is based on an analysis of the first 250 patients with both hematologic malignancy and COVID-19 registered from 74 countries. The analysis showed that the mortality risk (28% overall and increased to 42% among hospitalized patients with COVID-19) was heterogenous and unpredictable, further challenging doctors when allocating resources and determining which patients receive intensive care.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form